Making Sense of Urine Markers (SIU Innovators)
SIU Academy®. Porten S. 05/21/21; 315651 Topic: Laboratory (biomarkers, biopsy/pathology, etc.)
Sima Porten
Sima Porten
Learning Objectives
At the end of this programme, participants will be able to:
  • Evaluate the benefits and risks of various treatment options across the treatment continuum in BCa, RCC, and PCa.
  • Discuss strategies to identify and manage adverse events related to immunotherapy.
  • Evaluate the role of immunotherapy vs VEGF-targeted therapies for RCC.
  • Evaluate the role of imaging or biomarkers vs biopsy in active surveillance for localized prostate cancer.
  • Discuss strategies for managing oligometastatic disease.
  • Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies